Zuellig Pharma has established a new strategic partnership with Sumitomo Dainippon Pharma that will accelerate the growth of Meronem, a broad spectrum, injectable carbapenem antibiotic, in Vietnam, Thailand, Singapore, Philippines, Malaysia and Hong Kong.

Meronem has been used to successfully treat a wide variety of bacterial infections caused by gram-positive and gram-negative bacteria, and anaerobes. It was created by Sumitomo Dainippon Pharma and launched as MEROPEN® in Japan in 1995.

Zuellig Pharma Senior Vice President Commercial Solutions George Eassey said: “Sumitomo Dainippon Pharma is one of Japan’s leading pharmaceutical companies, with a strong track record of developing innovative products. We are naturally very proud to be their partner in Asia.

“Meronem is a global brand and we are confident that our strong relationships across the healthcare sector and in-depth understanding of local healthcare systems will help to deliver its benefits to more doctors and their patients,” Mr. Eassey added.

Sumitomo Dainippon Pharma Executive Officer, Senior Director, Global Business Development; International Business Management Shigeyuki Nishinaka, Ph.D. said: “We are proud to partner with Zuellig Pharma, to ensure continuing access to Meronem in Southeast Asia and Hong Kong.”

Zuellig Pharma has a long history of maximizing the potential of mature brands in markets across Asia. The company’s proven marketing, sales and distribution expertise and strong relationships with the healthcare community guarantees access to the product for many years to come.

“Together we aim to contribute our services to the critical care of as many severe bacterial infectious disease patients as possible in these countries,” Dr. Nishinaka added.